Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EPS (Weighted Average and Diluted) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 89.04% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.24 through Dec 2025, up 50.4% year-over-year, with the annual reading at -$0.29 for FY2025, 87.61% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Plus Therapeutics, down from -$0.04 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.01 in Q2 2025, with the low at -$3.56 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.98, with a median of -$0.68 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 1324.0% in 2022, then soared 98.59% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.28 in 2021, then plummeted by 742.86% to -$2.36 in 2022, then surged by 70.34% to -$0.7 in 2023, then increased by 4.29% to -$0.67 in 2024, then surged by 89.04% to -$0.07 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.07, -$0.04, and -$0.01 for Q4 2025, Q3 2025, and Q2 2025 respectively.